

Cyclodextrin polymers as carries for the platinum-based anticancer agent LA-12.

Valentina Giglio,^a Maurizio Viale,^b Massimiliano Monticone,^b Angela M. Aura^a Giuseppe Spoto,^a
Giovanni Natile,^c Francesco P. Intini,^c Graziella Vecchio^{a,*}

^a Dipartimento di Scienze Chimiche, Università di Catania, Viale A. Doria, 6, 95125 Catania (Italy)

^b IRCCS Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, U.O.C. Bioterapie, L.go R. Benzi, 10, 16132, Genova (Italy)

^c Dipartimento di Chimica, Università di Bari, Via E. Orabona, 4, 70125, Bari (Italy)




Figure 1S. ^1H NMR spectrum of oCyD (D_2O , 500 MHz)




Figure 2S. Volume size distribution of oCyD (red) and pCyD (black) in Tris buffer pH 7.4 at 25°C




Figure 3S: Intensity of scattered light (Kc/R₀P_θ) vs. oCyD concentration.




Figure 4S. ¹H NMR spectrum of pCyDFA (D₂O, 500 MHz)




Figure 5S. ^1H NMR spectrum of pCyDFA/LA-12 (D_2O , 500 MHz, aliphatic region)




Figure 6S: A) SPRI Response vs time after injecting sucrose solutions (0.0150, 0.0290, 0.0590, 0.0890, 0.1180 M in water); B) SPRI response vs sucrose refractive index.





Figure 7S: A) SPRI Response vs time after injecting oCyD solutions (0.001, 0.003, 0.005, 0.007, 0.010, 0.013 g/mL in TRIS buffer 10 mM, pH 7.4), B) Refractive index vs oCyD concentration (0.001, 0.003, 0.005, 0.007, 0.010, 0.013 g/mL in TRIS buffer 10 mM pH 7.4).





Figure 8S: A) SPRI Response vs time after injecting pCyD solutions (0.001, 0.003, 0.005, 0.007, 0.010 g/mL in TRIS buffer 10 mM pH, 7.4), B) Refractive index vs pCyD concentration (0.001, 0.003, 0.005, 0.007, 0.010 g/mL in TRIS buffer 10 mM pH 7.4).